CD19 and neoplasm: On the other hand, two studies reported an increased efficacy of TRAC KO anti-CD19 CAR T cells, one a non-significant increased survival in acute lymphoblastic leukemia (ALL) mouse model [29] and another demonstrating less tumor burden and CAR T cell exhaustion in Burkitt’s lymphoma [34].